Article Versions Notes

Maugeais M, Péron J, Dalle S, Boespflug A, Duruissaux M, Corbaux P, Reverdy T, Sahin G, Rabier A, Lopez J, et al. Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines. 2023; 11(1):83. https://doi.org/10.3390/biomedicines11010083

Maugeais, Madeleine, Julien Péron, Stéphane Dalle, Amélie Boespflug, Michaël Duruissaux, Pauline Corbaux, Thibault Reverdy, Gulsum Sahin, Aurélie Rabier, Jonathan Lopez, and et al. 2023. "Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study" Biomedicines 11, no. 1: 83. https://doi.org/10.3390/biomedicines11010083

Maugeais, M., Péron, J., Dalle, S., Boespflug, A., Duruissaux, M., Corbaux, P., Reverdy, T., Sahin, G., Rabier, A., Lopez, J., Freymond, N., & Maillet, D. (2023). Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines, 11(1), 83. https://doi.org/10.3390/biomedicines11010083